NAVIGATE
News
Groton, CT, September 14, 2022 – Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries,
Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced
Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced
Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries,
Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain
Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced
Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain
Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain
Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board
Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in
Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s
Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase
